Post-approval Registry Study to Evaluate the Continued Safety and Probable Benefit of the MID-C System for 5 Years Post-Implantation in Adolescent Idiopathic Scoliosis (AIS)

Status: Active_not_recruiting
Location: See all (15) locations...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The ApiFix MID-C System is a unidirectional expandable rod, designed to be connected unilaterally to the spine via 2 anchor points on the concave side of a scoliotic deformity above and below the apex of the major curvature to treat adolescent idiopathic scoliosis. The MID-C System is designed to act as an internal brace. Patients implanted with the device in the US within 2 years of FDA's approval of H17001 should be enrolled in the study. A minimum number of 200 patients will be enrolled in this study.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 10
Healthy Volunteers: f
View:

• Adolescent Idiopathic Scoliosis classified as Lenke Type 1 or Type 5 curves;

• Cobb angle between 35-60 degrees (inclusive);

• Flexible curve that that reduces to ≤ 30 degrees on lateral side-bending radiographs or as evident by traction x-ray;

• Kyphosis angles of ≤ 55 degrees measured from T5 to T12;

• Appropriate candidate for posterior surgical approach;

• Patient has good general health;

• Patient has no known hypersensitivity or allergies to titanium;

• Patient's guardian signs a written informed consent form (ICF).

Locations
United States
California
Rady Children's Hospital
San Diego
Florida
Wolfson children's hospital
Jacksonville
Georgia
Children's Hospital of Atlanta (CHOA)
Atlanta
Wellstar
Atlanta
Indiana
Riley Children's Health
Indianapolis
Kansas
Children's Mercy Hospital
Kansas City
Minnesota
Mayo Clinic
Rochester
Missouri
Women and Children's Hospital - University of Missouri Health Care
Columbia
Shriners Hospitals for Children
Saint Louis
Mississippi
Univ. of Mississippi Medical Center (UMMC)
Jackson
New York
Mount Sinai hospital
New York
Ohio
Rainbow babies and children
Cleveland
Dayton Children's Hospital
Dayton
South Dakota
Avera Health
Sioux Falls
Virginia
University of Virginia
Charlottesville
Time Frame
Start Date: 2020-05-31
Completion Date: 2030-06-30
Participants
Target number of participants: 200
Treatments
Experimental: MID-C treatment
Sponsors
Leads: Apifix

This content was sourced from clinicaltrials.gov